Feed KYNB
KY

Kyntra Bio, Inc. KYNB NASDAQ · Healthcare · United States

$1.56 -14.75% -$0.27

Market cap
$7.41M
Enterprise value
-$2.49M
P/E
0.2x
Forward P/E
-
PEG
-
P/S
1.4x
P/FCF
-
EV/EBITDA
-
ROIC
-204.1%
Gross margin
-2.0%
Net margin
657.7%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.11
Free float
88.1%

Sector

Healthcare

Industry

Biotechnology

CEO

Thane Wettig

Employees

34

Headquarters

San Francisco

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What to watch: Revenue fell by 64% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 658 USD is left as net profit.
  • What to watch: It reports a profit, yet spends more cash than it brings in.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy